The first-line therapy for advanced NSCLC that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death-ligand 1 (PD-L1) of 50% or higher, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The pembrolizumab and chemoradiation therapy in nsclc resulted in significantly increased rates of response as well as longer progression-free survival (PFS) than chemotherapy alone in the phase-2 trial.
top of page
bottom of page